Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,333,711 | $1,926,837 | $1,683,549 | $1,878,146 |
| - Cash | $92,710 | $80,871 | $78,964 | $76,247 |
| + Debt | $44,515 | $48,760 | $52,940 | $56,988 |
| Enterprise Value | $2,285,516 | $1,894,726 | $1,657,525 | $1,858,887 |
| Revenue | $12,880 | $12,455 | $8,726 | $10,730 |
| % Growth | 3.4% | 42.7% | -18.7% | – |
| Gross Profit | $11,201 | $9,494 | $7,641 | $9,470 |
| % Margin | 87% | 76.2% | 87.6% | 88.3% |
| EBITDA | -$102,059 | -$110,761 | -$105,351 | -$123,670 |
| % Margin | -792.4% | -889.3% | -1,207.3% | -1,152.6% |
| Net Income | -$103,433 | -$112,020 | -$89,289 | -$96,523 |
| % Margin | -803.1% | -899.4% | -1,023.3% | -899.6% |
| EPS Diluted | -1.78 | -1.93 | -1.55 | -1.69 |
| % Growth | 7.8% | -24.5% | 8.3% | – |
| Operating Cash Flow | -$88,151 | -$77,124 | -$111,489 | -$133,167 |
| Capital Expenditures | -$1,555 | -$875 | -$766 | -$967 |
| Free Cash Flow | -$89,706 | -$77,999 | -$112,255 | -$134,134 |